What's New

  • Show All
2015/07/15
Shionogi Announces the Continued Expansion of their Operations in Europe with the Launch of Shionogi Italy
2015/07/09
Shionogi to Determine the Contents of Stock Options as Compensation (Stock Acquisition Rights)
2015/06/24
SHIONOGI ANNOUNCES THAT NALDEMEDINE MET THE PRIMARY ENDPOINT IN ITS FIRST JAPANESE PHASE 3 STUDY FOR THE TREATMENT OF OPIOID-INDUCED CONSTIPATION IN CANCER PATIENTS
2015/06/24
Shionogi to Issue of Stock Options as Compensation (Stock Acquisition Rights) to Members of Board of Directors
2015/06/23
Notice of Convocation of the 150th Annual General Meeting of Shareholders (This Version reflects the partial correction described in "Partial Correction to Notice of Convocation of the 150th Annual General Meeting of Shareholders".)
2015/06/23
Partial Correction to Notice of Convocation of the 150th Annual General Meeting of Shareholders
2015/05/29
Notice of Convocation of the 150th Annual General Meeting of Shareholders and Items Disclosed on Internet Concerning Notice of Convocation
2015/05/26
Serotonin/Noradrenalin Reuptake Inhibitor Cymbalta® Capsule 20 mg, 30 mg New Indication Approved for Pain associated with Fibromyalgia
2015/05/18
Audio webcasting of FY2014 Financial Results
2015/05/11
FY2014 Financial Results
2015/05/11
Notice Concerning Partial Amendments to the Articles of Incorporation
2015/04/22
Notice of Revisions to Earnings and Dividend Forecasts
2015/04/10
ViiV Healthcare launched Triumeq®, a new single-pill regimen for the treatment of HIV infection in Japan